Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Lori J. Goldstein is active.

Publication


Featured researches published by Lori J. Goldstein.


Journal of Clinical Oncology | 2014

Prognostic Value of Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancers From Two Phase III Randomized Adjuvant Breast Cancer Trials: ECOG 2197 and ECOG 1199

Sylvia Adams; Robert Gray; Sandra Demaria; Lori J. Goldstein; Edith A. Perez; Lawrence N. Shulman; Silvana Martino; Molin Wang; Vicky Jones; Thomas J. Saphner; Antonio C. Wolff; William C. Wood; Nancy E. Davidson; George W. Sledge; J. A. Sparano; Sunil Badve

PURPOSEnRecent studies suggest that tumor-infiltrating lymphocytes (TILs) are associated with disease-free (DFS) and overall survival (OS) in operable triple-negative breast cancer (TNBC). We seek to validate the prognostic impact of TILs in primary TNBCs in two adjuvant phase III trials conducted by the Eastern Cooperative Oncology Group (ECOG).nnnPATIENTS AND METHODSnFull-face hematoxylin and eosin–stained sections of 506 tumors from ECOG trials E2197 and E1199 were evaluated for density of TILs in intraepithelial (iTILs) and stromal compartments (sTILs). Patient cases of TNBC from E2197 and E1199 were randomly selected based on availability of sections. For the primary end point of DFS, association with TIL scores was determined by fitting proportional hazards models stratified on study. Secondary end points were OS and distant recurrence–free interval (DRFI). Reporting recommendations for tumor marker prognostic studies criteria were followed, and all analyses were prespecified.nnnRESULTSnThe majority of 481 evaluable cancers had TILs (sTILs, 80%; iTILs, 15%). With a median follow-up of 10.6 years, higher sTIL scores were associated with better prognosis; for every 10% increase in sTILs, a 14% reduction of risk of recurrence or death (P = .02), 18% reduction of risk of distant recurrence (P = .04), and 19% reduction of risk of death (P = .01) were observed. Multivariable analysis confirmed sTILs to be an independent prognostic marker of DFS, DRFI, and OS.nnnCONCLUSIONnIn two national randomized clinical trials using contemporary adjuvant chemotherapy, we confirm that stromal lymphocytic infiltration constitutes a robust prognostic factor in TNBCs. Studies assessing outcomes and therapeutic efficacies should consider stratification for this parameter.


Journal of Clinical Oncology | 2008

Prognostic Utility of the 21-Gene Assay in Hormone Receptor–Positive Operable Breast Cancer Compared With Classical Clinicopathologic Features

Lori J. Goldstein; Robert Gray; Sunil Badve; Barrett H. Childs; Carl Yoshizawa; Steve Rowley; Steven Shak; Frederick L. Baehner; Peter M. Ravdin; Nancy E. Davidson; George W. Sledge; Edith A. Perez; Lawrence N. Shulman; Silvana Martino; Joseph A. Sparano

PURPOSEnAdjuvant! is a standardized validated decision aid that projects outcomes in operable breast cancer based on classical clinicopathologic features and therapy. Genomic classifiers offer the potential to more accurately identify individuals who benefit from chemotherapy than clinicopathologic features.nnnPATIENTS AND METHODSnA sample of 465 patients with hormone receptor (HR) -positive breast cancer with zero to three positive axillary nodes who did (n = 99) or did not have recurrence after chemohormonal therapy had tumor tissue evaluated using a 21-gene assay. Histologic grade and HR expression were evaluated locally and in a central laboratory.nnnRESULTSnRecurrence Score (RS) was a highly significant predictor of recurrence, including node-negative and node-positive disease (P < .001 for both) and when adjusted for other clinical variables. RS also predicted recurrence more accurately than clinical variables when integrated by an algorithm modeled after Adjuvant! that was adjusted to 5-year outcomes. The 5-year recurrence rate was only 5% or less for the estimated 46% of patients who have a low RS (< 18).nnnCONCLUSIONnThe 21-gene assay was a more accurate predictor of relapse than standard clinical features for individual patients with HR-positive operable breast cancer treated with chemohormonal therapy and provides information that is complementary to features typically used in anatomic staging, such as tumor size and lymph node involvement. The 21-gene assay may be used to select low-risk patients for abbreviated chemotherapy regimens similar to those used in our study or high-risk patients for more aggressive regimens or clinical trials evaluating novel treatments.


Journal of Clinical Oncology | 2008

Concurrent Doxorubicin Plus Docetaxel Is Not More Effective Than Concurrent Doxorubicin Plus Cyclophosphamide in Operable Breast Cancer With 0 to 3 Positive Axillary Nodes: North American Breast Cancer Intergroup Trial E 2197

Lori J. Goldstein; Anne O'Neill; Joseph A. Sparano; Edith A. Perez; Lawrence N. Shulman; Silvana Martino; Nancy E. Davidson

PURPOSEnThe combination of doxorubicin and cyclophosphamide (AC) is a standard adjuvant regimen. Doxorubicin and docetaxel (AT) is one of the most active cytotoxic regimens for metastatic breast cancer. The purpose of this trial was to determine whether adjuvant AT improved disease-free survival compared with AC in operable breast cancer.nnnPATIENTS AND METHODSnWomen with invasive breast cancer were eligible if there were one to three positive lymph nodes or if the node-negative tumor was greater than 1 cm. Patients were randomly assigned after surgery to receive doxorubicin (60 mg/m(2)) plus either cyclophosphamide (600 mg/m(2); AC) or docetaxel (60 mg/m(2); AT) given every 3 weeks for four cycles, followed by hormone therapy for patients with estrogen receptor (ER) and/or progesterone receptor (PR)-positive tumors.nnnRESULTSnThere were 2,882 eligible patients enrolled. After a median follow-up of 79.5 months, there was no significant difference in disease-free survival (DFS; 85% in both arms) or overall survival (91% v 92%) at 5 years. The hazard ratio for AC versus AT was 1.02 (95% CI for DFS, 0.86 to 1.22; P = .78). In an exploratory analysis of prespecified stratification factors by ER and PR expression there were trends toward improved DFS for AT in ER/PR-negative disease. Grade 3 neutropenia associated with fever or infection occurred more often with AT (26% v 10%; P < .05).nnnCONCLUSIONnAT did not improve DFS or overall survival in this population, and was associated with more toxicity.


Breast Cancer Research and Treatment | 2012

Prognostic value of biologic subtype and the 21-gene recurrence score relative to local recurrence after breast conservation treatment with radiation for early stage breast carcinoma: results from the Eastern Cooperative Oncology Group E2197 study

Lawrence J. Solin; Robert Gray; Lori J. Goldstein; Abram Recht; Frederick L. Baehner; Steven Shak; Sunil Badve; Edith A. Perez; Lawrence N. Shulman; Silvana Martino; Nancy E. Davidson; George W. Sledge; Joseph A. Sparano

The present study was performed to evaluate the significance of biologic subtype and 21-gene recurrence score relative to local recurrence and local–regional recurrence after breast conservation treatment with radiation. Eastern Cooperative Oncology Group E2197 was a prospective randomized clinical trial that compared two adjuvant systemic chemotherapy regimens for patients with operable breast carcinoma with 1–3 positive lymph nodes or negative lymph nodes with tumor size >1.0xa0cm. The study population was a subset of 388 patients with known 21-gene recurrence score and treated with breast conservation surgery, systemic chemotherapy, and definitive radiation treatment. Median follow-up was 9.7xa0years (rangexa0=xa03.7–11.6xa0years). The 10-year rates of local recurrence and local–regional recurrence were 5.4xa0% and 6.6xa0%, respectively. Neither biologic subtype nor 21-gene Recurrence Score was associated with local recurrence or local–regional recurrence on univariate or multivariate analyses (all Pxa0≥xa00.12). The 10-year rates of local recurrence were 4.9xa0% for hormone receptor positive, HER2-negative tumors, 6.0xa0% for triple negative tumors, and 6.4xa0% for HER2-positive tumors (Pxa0=xa00.76), and the 10-year rates of local–regional recurrence were 6.3, 6.9, and 7.2xa0%, respectively (Pxa0=xa00.79). For hormone receptor-positive tumors, the 10-year rates of local recurrence were 3.2, 2.9, and 10.1xa0% for low, intermediate, and high 21-gene recurrence score, respectively (Pxa0=xa00.17), and the 10-year rates of local–regional recurrence were 3.8, 5.1, and 12.0xa0%, respectively (Pxa0=xa00.12). For hormone receptor-positive tumors, the 21-gene recurrence score evaluated as a continuous variable was significant for local–regional recurrence (hazard ratio 2.66; Pxa0=xa00.03). The 10-year rates of local recurrence and local–regional recurrence were reasonably low in all subsets of patients. Neither biologic subtype nor 21-gene recurrence score should preclude breast conservation treatment with radiation.


Clinical Cancer Research | 2009

Relationship between Topoisomerase 2A RNA Expression and Recurrence after Adjuvant Chemotherapy for Breast Cancer

J. A. Sparano; Lori J. Goldstein; Barrett H. Childs; Steven Shak; Diana Brassard; Sunil Badve; Frederick L. Baehner; Roberto Bugarini; Steve Rowley; Edith A. Perez; Lawrence N. Shulman; Silvana Martino; Nancy E. Davidson; George W. Sledge; Robert Gray

Purpose: To perform an exploratory analysis of the relationship between gene expression and recurrence in operable hormone receptor (HR)–positive, human epidermal growth factor receptor 2 (HER2)–normal breast cancer patients treated with adjuvant doxorubicin-containing chemotherapy. Experimental Design: RNA was extracted from archived tumor samples derived from 378 patients with stage I to III HR-positive, HER2-normal breast cancer and analyzed by reverse transcription-PCR for a panel of 374 genes, including the 21-gene recurrence score (RS). Patients were randomized to receive adjuvant doxorubicin plus cyclophosphamide or docetaxel in trial E2197, with no difference in recurrence seen in the treatment arms. All available recurrent cases were selected plus a nonrecurrent cohort. Cox proportional hazard models were used to identify relationships between gene expression and recurrence. Results: TOP2A expression exhibited the strongest association with increased recurrence risk (P = 0.01), and was significantly associated with recurrence (P = 0.008) in a multivariate analysis adjusted for clinicopathologic features. Elevated TOP2A expression above the median was associated with a 2.6-fold increase (95% confidence interval, 1.3-5.2; P = 0.008) in risk of recurrence if the RS was <18, and a 2.0-fold increase (95% confidence interval, 1.2-3.2, P = 0.003) if there was an intermediate RS of 18 to 30. Conclusions: In patients with HR-positive, HER2-normal breast cancer, a population known to have a low incidence of TOP2A gene alterations thought to be predictive of anthracycline benefit, there is a range of TOP2A RNA expression that is strongly associated with recurrence after adjuvant anthracyclines, which provides information complementary to RS, indicating that it merits further evaluation as a prognostic and predictive marker. (Clin Cancer Res 2009;15(24):7693–700)


Clinical Cancer Research | 2011

Relationship between Quantitative GRB7 RNA Expression and Recurrence after Adjuvant Anthracycline Chemotherapy in Triple-Negative Breast Cancer

Joseph A. Sparano; Lori J. Goldstein; Barrett H. Childs; Steven Shak; Diana Brassard; Sunil Badve; Frederick L. Baehner; Roberto Bugarini; Steve Rowley; Edith A. Perez; Lawrence N. Shulman; Silvana Martino; Nancy E. Davidson; Paraic Kenny; George W. Sledge; Robert Gray

Purpose: To conduct an exploratory analysis of the relationship between gene expression and recurrence in patients with operable triple-negative breast cancer (TNBC) treated with adjuvant doxorubicin-containing chemotherapy. Experimental Design: RNA was extracted from archived tumor samples derived from 246 patients with stage I-III TNBC treated with adjuvant doxorubicin-containing chemotherapy, and was analyzed by quantitative reverse transcriptase PCR for a panel of 374 genes. The relationship between gene expression and recurrence was evaluated using weighted Cox proportional hazards model score tests. Results: Growth factor receptor bound protein 7 (GRB7) was the only gene for which higher expression was significantly associated with increased recurrence in TNBC (Korns adjusted P value = 0.04). In a Cox proportional hazards model adjusted for clinicopathologic features, higher GRB7 expression was associated with an increased recurrence risk (HR = 2.31; P = 0.04 using the median as the split). The 5-year recurrence rates were 10.5% [95% confidence intervals (CI), 7.8–14.1] in the low and 20.4% (95% CI, 16.5–25.0) in the high GRB7 groups. External validation in other datasets indicated that GRB7 expression was not prognostic in two adjuvant trials including variable systemic therapy, but in two other trials showed that high GBR7 expression was associated with resistance to neoadjuvant doxorubicin and taxane therapy. Conclusions: GRB7 was associated with an increased risk of recurrence in TNBC, suggesting that GRB7 or GRB7-dependent pathways may serve as potential biomarkers for therapeutic targets. Therapeutic targeting of one or more factors identified which function as interaction nodes or effectors should also be considered. Clin Cancer Res; 17(22); 7194–203. ©2011 AACR.


Cancer Research | 2009

Gene Expression Profiling of Phenotypically-Defined Hormone-Receptor Positive Breast Cancer: Evidence for Increased Transcriptional Activity of the Insulin Growth Factor Receptor Pathway and Other Pathways.

J. A. Sparano; Robert Gray; Lori J. Goldstein; Bh Childs; D. Brassard; Roberto Bugarini; Steve Rowley; J. Baker; Steven Shak; Sunil Badve; Fl Baehner; P. Kenny; E. Perez; Lawrence N. Shulman; Silvana Martino; George W. Sledge; Nancy E. Davidson

Background: Approximately 70% of all breast cancers are hormone receptor (HR)-positive tumors that are sensitive to endocrine therapy, but some patients have recurrence despite adjuvant endocrine therapy. We performed an exploratory analysis of gene expression in HR-pos operable breast cancer in order to identify potential novel therapeutic targets and biomarkers associated with recurrence. Methods: RNA was extracted from primary tumor samples obtained from 776 patients with stage I-III breast cancer treated with adjuvant chemohormonal therapy in trial E2197 (JCO 2008; 26: 4092-4099), of whom 458 had HR-pos disease (defined in a central lab; JCO 2008; 26: 2473). We evaluated RNA expression patterns (by quantitative RT-PCR using a panel of 371 rationally selected genes) in HR-pos cases compared with the HR-neg cases using weighted T statistics, and determined which genes in the HR-pos, HER2-neg group were associated with recurrence (using Cox proportional hazards model score test, Korn9s adjusted P value Results: The top 10 genes exhibiting significantly higher expression in the HR-pos group (p≤ 6.17e-160) included ESR1 plus 5 estrogen regulated genes, confirming our approach of evaluating gene expression in phenotypically-defined subsets. Other pathways that exhibited higher expression in the HR-pos group (among the 40 top genes with higher expression, p IRS1, IGFR1, IGFB2 ), Ras ( RhoB, RhoC, RAB27B, GGPS1 ), and HER pathways ( ERBB2, ERBB3, ERBB4 ), and other genes involved in apoptosis ( BCL2, BCL2L1, BAG1, NME6, BBC3 ), signaling ( MAPK3, SEMA3F, RXRA ), mismatch repair ( MSH3 ), cell cycle regulation ( CCND1 ), stress response ( HSPB1 ), and tumor suppressor genes ( TP53BP1, APC ). These patterns were similar in HER2-pos cases. Pathway analysis (Ingenuity) revealed substantial interconnectivity among these genes, especially between IGFR1 , ERB2/3/4 , MAPK3 , BCL2 , and CCND1 , but not RhoB/RhoC . Genes for which increased expression was associated with increased recurrence included those associated with proliferation ( TOP2A, AURKB, PLK1 ) and apoptosis ( BIRC5 - survivin). Conclusions: This exploratory analysis reveals several pathways that exhibit higher transcriptional expression in HR-pos disease, some of which are also associated with a higher risk of recurrence, suggesting that they may be potential therapeutic targets. This provides rationale for testing agents currently available in the clinic that inhibit the IGF and other pathways. Citation Information: Cancer Res 2009;69(24 Suppl):Abstract nr 5165.


Journal for ImmunoTherapy of Cancer | 2013

Towards an immunoscore for triple negative breast cancer (TNBC): lymphocytic infiltrate predicts outcome

Sylvia Adams; Robert Gray; Sandra Demaria; Lori J. Goldstein; Edith A Perez; Lawrence N. Shulman; Silvana Martino; Nancy E. Davidson; George W. Sledge; J. A. Sparano; Sunil Badve

Meeting abstractsnnEfforts are ongoing to further classify solid tumors by immunoscores, which have prognostic implications and may also have predictive value and identify targets for novel therapies to increase cure rates. TNBC are highly aggressive breast cancers, which are frequently infiltrated


Oncologist | 2004

Prognostic and Predictive Factors in Early-Stage Breast Cancer

Mary E. Cianfrocca; Lori J. Goldstein


Current Treatment Options in Oncology | 2001

Operable breast cancer.

Mary E. Cianfrocca; Lori J. Goldstein

Collaboration


Dive into the Lori J. Goldstein's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Barrett H. Childs

Memorial Sloan Kettering Cancer Center

View shared research outputs
Top Co-Authors

Avatar

Joseph A. Sparano

Albert Einstein College of Medicine

View shared research outputs
Researchain Logo
Decentralizing Knowledge